The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism.

Giuseppe Montalto, Melchiorre Cervello, Antonina Azzolina, Nadia Lampiasi, James A. Mccubrey, Kazuo Umezawa

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)
Original languageEnglish
Pages (from-to)35-44
Number of pages10
JournalCancer Letters
Volume322
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this